We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Chronic HCV Increases Risk for Renal Cancer

By LabMedica International staff writers
Posted on 19 Jul 2010
An enzyme-linked immunoassay (ELISA) and a molecular assay for ribonucleic acid (RNA) were used to test a large cohort for a specific viral infection. More...


The cohort was tested for the presence of antibodies to Hepatitis C virus (HCV) and their infectivity by the molecular test to establish their risk for renal cell carcinoma (RCC).

The 67,063 participants were tested for HCV between 1997 and 2006, and followed to monitor development of RCC until April 2008 and about 5% were positive for the virus. RCC developed in 17 of the 3,057 (0.6%) who were HCV positive and in only 0.3% of 64,006 HCV negative participants. Among the HCV-positive RCC patients, the HCV RNA viral levels and genotypes, and liver histology were recorded.

The RCC cases in HCV positive patients included eight clear cell cancers, six papillary cancers, two mixed clear cell/papillary, and one undifferentiated neoplasm.

Among participants diagnosed with RCC, HCV positive patients were of a significantly younger average age than HCV negative patients were. Men were 2.4 times more likely to develop the malignancy than women were, and Afro-Americans had about a 40% higher risk than any other racial or ethnic group.

Chronic hepatitis C is primarily a disease of the liver, but it can also contribute to problems elsewhere in the body. Stuart C. Gordon, M.D., from Henry Ford Hospital, (Detroit, MI, USA) said, "These results add to growing literature that shows that the hepatitis C virus causes disease that extends beyond the liver, and in fact most of our HCV-infected kidney cancer patients had only minimal liver damage". The results were published in the April 2010 issue of Cancer Epidemiology Biomarkers and Prevention.

Related Links:

Henry Ford Hospital



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.